Home > Courses > Buprenorphine in New York State: A Clinical Overview

Buprenorphine in New York State: A Clinical Overview

Original Release Date: 11/17/2020
Termination Date: 11/13/2021
Review Date: 2/18/2021
  • Kelly Ramsey, MD, MPH, MA, FACP
    Associate Chief of Addiction Medicine
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Identify how buprenorphine fits into a harm reduction framework.
  2. Review federal and state requirements for prescribing buprenorphine.
  3. Discuss perceived challenges in buprenorphine implementation and strategies to overcome them.
Presenter Bio
Kelly Ramsey, MD, MPH, MA, FACP
Kelly S. Ramsey, MD is an internal medicine physician who has treated substance use disorder since 2004. She worked as Medical Director of an academic center-based OTP in the South Bronx before working for a decade for a large FQHC in the Hudson Valley where she created and grew a MAT program for OUD and AUD to 10 sites and 1500 patients. Dr. Ramsey currently works as the Associate Chief of Addiction Medicine at NYS OASAS. Dr. Ramsey has provided expert advice to the New York State Department of Health AIDS Institute by serving on numerous committees for over a decade, including the Co-Chair of the HIV Quality of Care Advisory Committee (QAC), and, until starting at OASAS in June 2020, Vice-Chair of the Substance Use Guidelines Committee for the HIV Clinical Practice Guidelines(a collaboration with Johns Hopkins University)and Co-Chair of the Office of Drug User Health’s NYS Buprenorphine Advisory Group. Dr. Ramsey was the recipient of the NYS DOH Commissioner’s Special Recognition Award for contributions to drug user health in NYS in December 2018. Dr. Ramsey serves as the HCV and Drug User Health Champion for the Capital District for Mount Sinai to provide educational support for CEI (Clinician Education Initiative) on HIV, HCV, PEP, PrEP, and Drug User Health (MAT, opioid overdose prevention, harm reduction) through the NYS DOH (live presentations, webinars, planning initiatives). Dr. Ramsey is the President-Elect for the NYSAM BOD and serves as Chair of their Education/CME Committee.
Continuing Education Credit

The target audience is health care professionals interested in HIV/HCV/STD/Drug User Health continuing medical education.

Accreditation Statement


The University of Rochester School of Medicine and Dentistry is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

The University of Rochester School of Medicine and Dentistry designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


The University of Rochester Center for Nursing Professional Development is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. 

1.0 Nursing Contact Hours will be provided. 


The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based home study activity “Buprenorphine in New York State: A Clinical Overview”, ACPE #0044-9999-18-039-H01-P, will award 1.0 contact hours or 0.10 pharmacy education credit.  

No partial credit will be awarded.

Disclosure Statement

ACCME Standards for Commercial Support of CME require that presentations be free of commercial bias and that any information regarding commercial products/services be based on scientific methods generally accepted by the medical community. When discussing therapeutic options, speakers are requested to use only generic names. If they use a trade name, then those of several companies should be used. If a presentation includes discussion of any unlabeled or investigational use of a commercial product, speakers are required to disclose this to the participants. 

No commercial funds have been received to support this educational activity. 

Planning Committee and Speakers Disclosures: 

A conflict of interest (COI) occurs when an individual has an opportunity to affect educational content about healthcare products or services of a commercial interest with which she/he has a financial relationship and/or personal relationship.  

The following planners and presenters of this CME activity have disclosed no relevant personal or financial relationships with any commercial interests pertaining to this activity: Jessica Steinke, MPH; Terri L. Wilder, MSW; Kelly S. Ramsey, MD, MPH, MA, FACP; Ross Sullivan, MD, Monica Barbosu, MD, PhD; Tamara Eis, MS, RN-BC; Oksana Babiy, BS.

Antonio Urbina, MD, has had the following relevant financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Scientific Advisory Panel: Gilead, VIIV and Merck.

Presenter: Kelly Ramsey, MD, MPH, MA, FACP has had no relevant financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity.


  • This online video and post-activity evaluation are 60 min. in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must pass the quiz with a score of 80% or higher to receive the CE certificate/credit.
  • If successful, you will be provided instructions to print your CE certificate/credit.

Bibliographic Sources to Allow for Further Study: